Galmed Pharmaceuticals LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Galmed Pharmaceuticals reports its fiscal year 2024 results, highlighting a strategic shift towards oncology and cardiometabolic indications while managing operating losses.
NASDAQ
20-F: Galmed Pharmaceuticals Reports Financial Results for Fiscal Year 2023, Focuses on PSC Development
Galmed Pharmaceuticals reports a reduced net loss for 2023 and outlines its strategic focus on developing Aramchol for Primary Sclerosing Cholangitis (PSC).